Breaking New Ground: SamanTree Medical Secures $14M to Revolutionize Cancer Surgery with Histolog® Scanner

In a significant stride forward for surgical oncology, SamanTree Medical SA is thrilled to announce the successful raising of €14 million in its latest funding round. This Swiss-based company, a spin-off from the prestigious Ecole Polytechnique Fédérale de Lausanne (EPFL), is pioneering a transformative innovation in the field of cancer surgery with its flagship product, the Histolog® Scanner. Designed to provide real-time, high-resolution imaging of tumor margins during surgical procedures, the Histolog® Scanner enables surgeons to assess the complete removal of cancerous tissue with unprecedented accuracy. This critical advancement not only aims to enhance patient outcomes by drastically reducing the rates of re-operation but also strives to elevate the standard of care in operating rooms globally. With this new funding, SamanTree Medical is poised to accelerate its product development and pave the way for regulatory approvals, ensuring that healthcare professionals can leverage this cutting-edge technology in their fight against cancer. The dedicated team of experts behind SamanTree Medical is passionate about transforming the surgical landscape and is committed to delivering high-quality solutions that prioritize patient well-being. As the company looks to the future, the infusion of capital will significantly bolster their R&D efforts, allowing them to refine the Histolog® Scanner and expand its deployment across medical facilities. With a vision to redefine surgical efficacy and enhance quality of life for patients, SamanTree Medical is on a trajectory towards becoming the gold standard in real-time histological assessment. For more information on their revolutionary technologies and upcoming developments, visit their [linktree](https://linktr.ee/SamanTree).